Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 3, 2025 • 7:01 PM ET

Date/Time Source News Release
04/03/2025 04:01 PM EDT Business Wire Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
03/17/2025 04:01 PM EDT Business Wire Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
03/06/2025 04:05 PM EST Business Wire Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
02/06/2025 08:05 AM EST Business Wire Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
01/02/2025 03:05 PM EST Business Wire Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
12/30/2024 04:15 PM EST Business Wire Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec
12/19/2024 02:30 AM EST PR Newswire Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
12/19/2024 02:30 AM EST Business Wire Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
11/19/2024 04:15 PM EST Business Wire Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
11/12/2024 04:01 PM EST Business Wire Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Page

Additional News

As of April 3, 2025 • 7:01 PM ET

Date/Time Source News Release
04/03/2025 05:21 PM EDT SeekingAlpha Eli Lilly to leverage Sangamo capsid technology for CNS disease therapies
03/17/2025 06:29 PM EDT SeekingAlpha Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript
03/17/2025 05:10 PM EDT Zacks Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
03/17/2025 04:07 PM EDT SeekingAlpha Sangamo Therapeutics GAAP EPS of -$0.11 misses by $0.02, revenue of $7.55M misses by $4.15M
03/17/2025 10:00 AM EDT SeekingAlpha Here are the major earnings after the close today
03/17/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, March 17th, 2025
03/17/2025 05:31 AM EDT US Earnings Reports Expected earnings - Sangamo Therapeutics Inc.
03/16/2025 09:47 AM EDT SeekingAlpha Wasatch Ultra Growth Fund Q4 2024 Commentary
03/16/2025 08:00 AM EDT SeekingAlpha Earnings week ahead: FDX, GIS, NIO, XPEV, MU, NKE, CCL, ACN and more
03/11/2025 05:10 PM EDT Zacks Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.